Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of CT-P52 Auto-injector vs Pre-filled Syringe in Healthy Male Subjects
NCT07367958Phase 1Completed
- Sponsor
- Celltrion
- Start
- Jan 2026
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CT-P52 in plaque psoriasis (2 arms), sponsored by Celltrion. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Infinity at Day 85 and Maximum Observed Serum Concentration at Day 85. Started Jan 2026; status: completed.
02
Drugs
CT-P52
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07367958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07367958.